NVCR - Novocure Ltd

NVCR - Novocure Ltd

https://www.novocure.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts

Motley Fool • 2 weeks, 3 days ago • score: -0.08

Investment bank analysts up and down Wall Street are pounding the table on these stocks.

NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer

Zacks Commentary • 3 weeks, 3 days ago • score: 0.25

NovoCure submits a PMA to the FDA for TTFields therapy in pancreatic cancer, aiming to expand its oncology reach.

Top 3 Health Care Stocks That May Explode In July - HCA Healthcare ( NYSE:HCA ) , Molina Healthcare ( NYSE:MOH )

Benzinga • 1 month, 2 weeks ago • score: 0.09

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.

Novocure: Steady Ahead of Key Milestones

Motley Fool • 1 month, 3 weeks ago • score: -0.08

Here's our initial take on Novocure's ( NASDAQ: NVCR ) fiscal 2025 second-quarter financial report.Novocure reported no surprises in its latest quarter, with revenue up 6% for the year and both revenue and loss per share topping Wall Street expectations.

NovoCure ( NVCR ) Reports Q2 Loss, Tops Revenue Estimates

Zacks Commentary • 1 month, 3 weeks ago • score: 0.07

NovoCure (NVCR) delivered earnings and revenue surprises of +7.69% and +3.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday - BrightSpire Capital ( NYSE:BRSP ) , Bluerock Homes Trust ( AMEX:BHM )

Benzinga • 2 months, 1 week ago • score: 0.02

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

NovoCure ( NVCR ) Soars 5.3%: Is Further Upside Left in the Stock?

Zacks Commentary • 2 months, 2 weeks ago • score: 0.14

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

What Makes NovoCure ( NVCR ) a New Buy Stock

Zacks Commentary • 2 months, 4 weeks ago • score: 0.32

NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.

52W High

$34.13

52W Low

$10.87

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.58

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

909.09

EV/EBITDA (<8 favorable)

-6.92

EV/Revenue (<3 favorable)

1.84

P/S (TTM) (<3 favorable)

2.18

P/B (<3 favorable)

3.93

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

9.81%

Institutions (25–75% balanced)

86.45%

Shares Outstanding

111,799,000

Float

94,148,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

630,160,000

Gross Profit (TTM)

482,335,000

EPS (TTM)

-1.56

Profit Margin (>10% good)

-0.27%

Operating Margin (TTM) (higher better)

-0.25%

ROE (TTM) (>15% strong)

-0.48%

EPS YoY (Quarterly) (>10% good)

-0.06

Revenue YoY (Quarterly) (>8% good)

0.06

Momentum

Bearish momentum

Value

-0.3122

Previous

-0.3671

Trend

Rising

Signal Cross

No cross

As of

Sep. 05, 2025